Summit Therapeutics Shares Drop After Releasing Late-Stage Trial Data for Lung Cancer Drug
Summit Therapeutics' stock fell approximately 1% in premarket trading after the company released updated overall survival data from a late-stage trial of ivonescimab, its lung cancer therapy developed with Akeso. The drug is being co-developed by Summit and Chinese biotech firm Akeso.
Tickers: $SMMT
Topics: cancer therapy late-stage trial data pharmaceuticals